Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.
Hansa Biopharma AB announced a virtual event featuring transplant experts to discuss the Phase 3 results of their imlifidase treatment for highly sensitized kidney transplant patients. The event aims to provide insights into the clinical relevance of these results and their potential impact on the standard of care for transplant patients, highlighting the company’s commitment to addressing the needs of this challenging patient group.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK132.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare immunological conditions.
Average Trading Volume: 678,042
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.71B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.